Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E M Griffiths

Showing results (281-290 of 337) with videos related to

Pageof 34
Sort By:
The Journal of Investigative Dermatology|February 24, 2015
A Genome-Wide Association Study Identifies the Skin Color Genes IRF4, MC1R, ASIP, and BNC2 Influencing Facial Pigmented SpotsLeonie C Jacobs, Merel A Hamer, David A Gunn, et al.
Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 11, 2012
Facial appearance reflects human familial longevity and cardiovascular disease risk in healthy individualsDavid A Gunn, Anton J M de Craen, Joanne L Dick, et al.
The Journal of Investigative Dermatology|April 18, 2016
Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-AnalysisZenas Z N Yiu, Lesley S Exton, Zarif Jabbar-Lopez, et al.
The Lancet. Public Health|March 29, 2024
Estimating the burden of vitiligo: a systematic review and modelling studyJennifer Akl, Solam Lee, Hyun Jeong Ju, et al.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
The British Journal of Dermatology|January 19, 2023
Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on PsoriasisJulia-Tatjana Maul, Fabienne Fröhlich, Lara Valeska Maul, et al.
The New England Journal of Medicine|July 10, 2014
Secukinumab in plaque psoriasis--results of two phase 3 trialsRichard G Langley, Boni E Elewski, Mark Lebwohl, et al.
The Journal of Investigative Dermatology|March 22, 2003
Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosisKati Asumalahti, Mahreen Ameen, Sari Suomela, et al.
The Journal of Clinical Investigation|August 9, 2008
The PKC inhibitor AEB071 may be a therapeutic option for psoriasisHans Skvara, Markus Dawid, Elise Kleyn, et al.
Pageof 34

Showing results (281-290 of 337) with videos related to

Sort By:
Pageof 34
The Journal of Investigative Dermatology|February 24, 2015
A Genome-Wide Association Study Identifies the Skin Color Genes IRF4, MC1R, ASIP, and BNC2 Influencing Facial Pigmented SpotsLeonie C Jacobs, Merel A Hamer, David A Gunn, et al.
Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 11, 2012
Facial appearance reflects human familial longevity and cardiovascular disease risk in healthy individualsDavid A Gunn, Anton J M de Craen, Joanne L Dick, et al.
The Journal of Investigative Dermatology|April 18, 2016
Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-AnalysisZenas Z N Yiu, Lesley S Exton, Zarif Jabbar-Lopez, et al.
The Lancet. Public Health|March 29, 2024
Estimating the burden of vitiligo: a systematic review and modelling studyJennifer Akl, Solam Lee, Hyun Jeong Ju, et al.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
The British Journal of Dermatology|January 19, 2023
Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on PsoriasisJulia-Tatjana Maul, Fabienne Fröhlich, Lara Valeska Maul, et al.
The New England Journal of Medicine|July 10, 2014
Secukinumab in plaque psoriasis--results of two phase 3 trialsRichard G Langley, Boni E Elewski, Mark Lebwohl, et al.
The Journal of Investigative Dermatology|March 22, 2003
Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosisKati Asumalahti, Mahreen Ameen, Sari Suomela, et al.
The Journal of Clinical Investigation|August 9, 2008
The PKC inhibitor AEB071 may be a therapeutic option for psoriasisHans Skvara, Markus Dawid, Elise Kleyn, et al.
Pageof 34